1. Market Research
  2. > Dental Pain - Pipeline Review, H2 2013

Dental Pain - Pipeline Review, H2 2013

  • November 2013
  • -
  • Global Markets Direct
  • -
  • 44 pages

Dental Pain - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Dental Pain - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Dental Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dental Pain. Dental Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dental Pain.
- A review of the Dental Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dental Pain pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Dental Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dental Pain pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Dental Pain - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dental Pain Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Dental Pain 7
Dental Pain Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Dental Pain Therapeutics - Products under Development by Companies 12
Companies Involved in Dental Pain Therapeutics Development 13
Eli Lilly and Company 13
Pfizer Inc. 14
Bayer AG 15
NeuroDiscovery Ltd 16
Array BioPharma Inc. 17
SCOLR Pharma, Inc. 18
Iroko Pharmaceuticals, LLC 19
Dental Pain - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
ARRY-797 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
NSL-101 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
PF-05089771 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
naproxen nanoformulation - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
LY-3023703 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
ibuprofen ER - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
(diphenhydramine hydrochloride + naproxen sodium) - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Dental Pain Therapeutics - Drug Profile Updates 37
Dental Pain Therapeutics - Discontinued Products 38
Dental Pain Therapeutics - Dormant Products 39
Dental Pain - Product Development Milestones 41
Featured News and Press Releases 41
Jun 21, 2012: Iroko Pharma Announces Phase III Study Results Of Diclofenac 41
Nov 04, 2011: Phase II Results For Nano-formulated NSAIDs Under Development At Iroko Pharmaceuticals To Be Reported At ACR Meeting 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44



List of Tables

Number of Products Under Development for Dental Pain, H2 2013 7
Products under Development for Dental Pain - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Late Stage Development, H2 2013 10
Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
Products under Development by Companies, H2 2013 12
Eli Lilly and Company, H2 2013 13
Pfizer Inc., H2 2013 14
Bayer AG, H2 2013 15
NeuroDiscovery Ltd, H2 2013 16
Array BioPharma Inc., H2 2013 17
SCOLR Pharma, Inc., H2 2013 18
Iroko Pharmaceuticals, LLC, H2 2013 19
Assessment by Monotherapy Products, H2 2013 20
Assessment by Combination Products, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 25
Dental Pain Therapeutics - Drug Profile Updates 37
Dental Pain Therapeutics - Discontinued Products 38
Dental Pain Therapeutics - Dormant Products 39
Dental Pain Therapeutics - Dormant Products (Contd..1) 40



List of Figures

Number of Products under Development for Dental Pain, H2 2013 7
Products under Development for Dental Pain - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Late Stage Products, H2 2013 10
Mid Clinical Stage Products, H2 2013 11
Assessment by Monotherapy Products, H2 2013 20
Assessment by Combination Products, H2 2013 21
Assessment by Route of Administration, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Molecule Type, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 25



Companies Mentioned

Eli Lilly and Company
Pfizer Inc.
Bayer AG
NeuroDiscovery Ltd
Array BioPharma Inc.
SCOLR Pharma, Inc.
Iroko Pharmaceuticals, LLC

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.